Compare EPRT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | ERAS |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.5B |
| IPO Year | 2018 | 2021 |
| Metric | EPRT | ERAS |
|---|---|---|
| Price | $31.50 | $9.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $36.79 | $14.25 |
| AVG Volume (30 Days) | 2.0M | ★ 9.3M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | 11.30 | ★ 36.23 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $561,219,000.00 | N/A |
| Revenue This Year | $17.12 | N/A |
| Revenue Next Year | $16.27 | N/A |
| P/E Ratio | $112.11 | ★ N/A |
| Revenue Growth | ★ 24.82 | N/A |
| 52 Week Low | $28.95 | $1.06 |
| 52 Week High | $34.73 | $24.28 |
| Indicator | EPRT | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 34.75 |
| Support Level | $29.30 | $2.07 |
| Resistance Level | $31.79 | $17.17 |
| Average True Range (ATR) | 0.63 | 1.55 |
| MACD | -0.03 | -0.85 |
| Stochastic Oscillator | 24.40 | 8.09 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.